Welcome to our dedicated page for Universe Pharmaceuticals news (Ticker: UPC), a resource for investors and traders seeking the latest updates and insights on Universe Pharmaceuticals stock.
Universe Pharmaceuticals INC reports developments tied to its role as a pharmaceutical producer and distributor in China. The company manufactures, markets, sells and distributes traditional Chinese medicine derivatives products targeting elderly consumers, and also distributes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces and dietary supplements made by third-party pharmaceutical companies.
Recurring news for UPC includes operating and financial results, product-distribution activity, Nasdaq Capital Market listing compliance notices, delayed annual-report matters, share consolidations and capital-structure changes such as the implementation of a dual-class ordinary share structure.
Universe Pharmaceuticals has priced its initial public offering (IPO) of 5,000,000 ordinary shares at US$5.00 each, aiming for gross proceeds of US$25 million. The shares will trade on the Nasdaq Global Market under the ticker symbol UPC starting March 23, 2021. The offering closes on or about March 25, 2021, subject to conditions. Proceeds will fund manufacturing upgrades, R&D, marketing, and working capital. Univest Securities, LLC is the underwriter, with a 45-day option for an additional 750,000 shares.